Changes in adrenergic receptors in the pregnant human uterine cervix following mifepristone or placebo treatment in the first trimester

L. Kovács, G. Falkay

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

There is increasing evidence that the antiprogesterone mifepristone (RU-486) can dilate the cervix of pregnant women. The uterine and cervical smooth muscle contractile reponse to adrenergic agonists is regulated by the steroidal environment. This study was undertaken to assess the effects of treatment with RU-486 on the concentrations of alpha- and beta-adrenoceptors in cervical crude membranes from pregnant women using a radioligand binding assay. A special needle biopsy technique was used for human cervical specimens. The probable relative oestrogen dominance due to the antiprogesterone treatment selectively decreased the alpha-2 adrenoceptor in human cervix at an early stage of gestation. This finding was similar to that reported earlier in pregnant rabbits. The existence of a functionally distinct alpha-2 adrenergic receptor subtype will have important implications for our understanding of the contractile activity of the cervix.

Original languageEnglish
Pages (from-to)119-121
Number of pages3
JournalHuman Reproduction
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 1993

Keywords

  • Adrenergic receptors
  • Antiprogestogen
  • Cervix

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Changes in adrenergic receptors in the pregnant human uterine cervix following mifepristone or placebo treatment in the first trimester'. Together they form a unique fingerprint.

  • Cite this